X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs IPCA LABS - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. IPCA LABS WOCKHARDT LTD./
IPCA LABS
 
P/E (TTM) x -11.6 36.4 - View Chart
P/BV x 2.3 3.5 67.2% View Chart
Dividend Yield % 1.4 0.1 954.7%  

Financials

 WOCKHARDT LTD.   IPCA LABS
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
IPCA LABS
Mar-17
WOCKHARDT LTD./
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,129643 175.6%   
Low Rs627503 124.7%   
Sales per share (Unadj.) Rs363.1254.4 142.7%  
Earnings per share (Unadj.) Rs-20.416.1 -127.2%  
Cash flow per share (Unadj.) Rs-7.029.8 -23.4%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.10.2 652.5%  
Book value per share (Unadj.) Rs301.8194.6 155.1%  
Shares outstanding (eoy) m110.55126.20 87.6%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.42.3 107.4%   
Avg P/E ratio x-42.935.7 -120.4%  
P/CF ratio (eoy) x-125.919.2 -654.2%  
Price / Book Value ratio x2.92.9 98.8%  
Dividend payout %-48.96.2 -785.9%   
Avg Mkt Cap Rs m97,06372,300 134.3%   
No. of employees `0006.813.3 50.9%   
Total wages/salary Rs m9,6656,960 138.9%   
Avg. sales/employee Rs Th5,931.82,413.5 245.8%   
Avg. wages/employee Rs Th1,428.1523.2 273.0%   
Avg. net profit/employee Rs Th-334.0152.4 -219.1%   
INCOME DATA
Net Sales Rs m40,14632,106 125.0%  
Other income Rs m1,143226 506.2%   
Total revenues Rs m41,28932,332 127.7%   
Gross profit Rs m1284,448 2.9%  
Depreciation Rs m1,4891,730 86.1%   
Interest Rs m2,253241 935.5%   
Profit before tax Rs m-2,4722,703 -91.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-211675 -31.3%   
Profit after tax Rs m-2,2602,028 -111.5%  
Gross profit margin %0.313.9 2.3%  
Effective tax rate %8.525.0 34.2%   
Net profit margin %-5.66.3 -89.1%  
BALANCE SHEET DATA
Current assets Rs m46,16017,340 266.2%   
Current liabilities Rs m19,2589,559 201.5%   
Net working cap to sales %67.024.2 276.5%  
Current ratio x2.41.8 132.1%  
Inventory Days Days101100 100.4%  
Debtors Days Days9457 165.4%  
Net fixed assets Rs m40,16520,779 193.3%   
Share capital Rs m553252 219.0%   
"Free" reserves Rs m32,81424,499 133.9%   
Net worth Rs m33,36724,553 135.9%   
Long term debt Rs m31,9033,517 907.0%   
Total assets Rs m89,68739,595 226.5%  
Interest coverage x-0.112.2 -0.8%   
Debt to equity ratio x1.00.1 667.4%  
Sales to assets ratio x0.40.8 55.2%   
Return on assets %05.7 -0.1%  
Return on equity %-6.88.3 -82.0%  
Return on capital %-0.310.5 -3.2%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m9,12115,617 58.4%   
Fx outflow Rs m2,1335,828 36.6%   
Net fx Rs m6,9889,790 71.4%   
CASH FLOW
From Operations Rs m-2,6952,764 -97.5%  
From Investments Rs m-6,863-1,432 479.3%  
From Financial Activity Rs m12,545-1,591 -788.3%  
Net Cashflow Rs m3,010-259 -1,163.2%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 11.4 20.2%  
FIIs % 7.7 25.3 30.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   67,757 36,892 183.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare WOCKHARDT LTD. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jun 20, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 8-QTR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS